Leads Biolabs’ Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL-051
NANJING, China, August 4, 2026 Leads Biolabs announced that its partner Oblenio Bio, a company jointly established with Aditum...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NANJING, China, August 4, 2026 Leads Biolabs announced that its partner Oblenio Bio, a company jointly established with Aditum...
